Last reviewed · How we verify
Ropivacaine 0.5% Injectable Solution
Ropivacaine 0.5% Injectable Solution, marketed by Rothman Institute Orthopaedics, is an established anesthetic in the orthopedic segment. The key composition patent expires in 2028, providing a clear period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | Ropivacaine 0.5% Injectable Solution |
|---|---|
| Also known as | Continous femoral nerve block, Popliteal plexus block, interscalene, Erector Spinae Plane Block, naropeine 0.5% |
| Sponsor | Rothman Institute Orthopaedics |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China. (PHASE3)
- CPL-01 in the Management of Postoperative Pain After Bunionectomy (PHASE3)
- Zynrelef Versus Adductor Canal Block (PHASE4)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
- Intrathecal MoRphine Versus Transabdominal Plane Block (TAP) Block for AnalGesic Management in Elective Caesarean Section (PHASE4)
- Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations (PHASE4)
- Post Operative Infusion Pump Pain Study (PHASE4)
- The Impact of Local Anesthetic Dilution on Possible Blinding for Nerve Blocks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: